200 related articles for article (PubMed ID: 24819754)
1. Enhancement of the uptake and cytotoxic activity of doxorubicin in cancer cells by novel cRGD-semipeptide-anchoring liposomes.
Battistini L; Burreddu P; Sartori A; Arosio D; Manzoni L; Paduano L; D'Errico G; Sala R; Reia L; Bonomini S; Rassu G; Zanardi F
Mol Pharm; 2014 Jul; 11(7):2280-93. PubMed ID: 24819754
[TBL] [Abstract][Full Text] [Related]
2. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
[TBL] [Abstract][Full Text] [Related]
3. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats.
Chen Z; Deng J; Zhao Y; Tao T
Int J Nanomedicine; 2012; 7():3803-11. PubMed ID: 22888235
[TBL] [Abstract][Full Text] [Related]
4. Anticancer cationic ruthenium nanovectors: from rational molecular design to cellular uptake and bioactivity.
Mangiapia G; Vitiello G; Irace C; Santamaria R; Colonna A; Angelico R; Radulescu A; D'Errico G; Montesarchio D; Paduano L
Biomacromolecules; 2013 Aug; 14(8):2549-60. PubMed ID: 23705931
[TBL] [Abstract][Full Text] [Related]
5. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
Wang F; Chen L; Zhang R; Chen Z; Zhu L
J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
[TBL] [Abstract][Full Text] [Related]
6. Liposome armed with herpes virus-derived gH625 peptide to overcome doxorubicin resistance in lung adenocarcinoma cell lines.
Perillo E; Porto S; Falanga A; Zappavigna S; Stiuso P; Tirino V; Desiderio V; Papaccio G; Galdiero M; Giordano A; Galdiero S; Caraglia M
Oncotarget; 2016 Jan; 7(4):4077-92. PubMed ID: 26554306
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
8. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
[TBL] [Abstract][Full Text] [Related]
9. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
10. Polyethylene sebacate doxorubicin nanoparticles: role of carbohydrate anchoring on in vitro and in vivo anticancer efficacy.
Pranatharthiharan S; Patel MD; Malshe VC; Devarajan PV
Drug Deliv; 2016 Oct; 23(8):2980-2989. PubMed ID: 26786706
[TBL] [Abstract][Full Text] [Related]
11. A Novel Folate-Targeted Nanoliposomal System of Doxorubicin for Cancer Targeting.
Lohade AA; Jain RR; Iyer K; Roy SK; Shimpi HH; Pawar Y; Rajan MG; Menon MD
AAPS PharmSciTech; 2016 Dec; 17(6):1298-1311. PubMed ID: 26689406
[TBL] [Abstract][Full Text] [Related]
12. Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery.
Caracciolo G; Palchetti S; Digiacomo L; Chiozzi RZZ; Capriotti AL; Amenitsch H; Tentori PM; Palmieri V; Papi M; Cardarelli F; Pozzi D; Laganà A
ACS Appl Mater Interfaces; 2018 Jul; 10(27):22951-22962. PubMed ID: 29905462
[TBL] [Abstract][Full Text] [Related]
13. pH and redox dual responsive nanoparticle for nuclear targeted drug delivery.
K C RB; Thapa B; Xu P
Mol Pharm; 2012 Sep; 9(9):2719-29. PubMed ID: 22876763
[TBL] [Abstract][Full Text] [Related]
14. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin.
Mamasheva E; O'Donnell C; Bandekar A; Sofou S
Mol Pharm; 2011 Dec; 8(6):2224-32. PubMed ID: 21899300
[TBL] [Abstract][Full Text] [Related]
16. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
17. Smart Lipid-Polysaccharide Nanoparticles for Targeted Delivery of Doxorubicin to Breast Cancer Cells.
Curcio M; Brindisi M; Cirillo G; Frattaruolo L; Leggio A; Rago V; Nicoletta FP; Cappello AR; Iemma F
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216501
[TBL] [Abstract][Full Text] [Related]
18. Glycol Chitosan-Docosahexaenoic Acid Liposomes for Drug Delivery: Synergistic Effect of Doxorubicin-Rapamycin in Drug-Resistant Breast Cancer.
Kim MW; Niidome T; Lee R
Mar Drugs; 2019 Oct; 17(10):. PubMed ID: 31614820
[TBL] [Abstract][Full Text] [Related]
19. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
[TBL] [Abstract][Full Text] [Related]
20. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy.
Lale SV; R G A; Aravind A; Kumar DS; Koul V
Biomacromolecules; 2014 May; 15(5):1737-52. PubMed ID: 24689987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
